Last week saw the 8th Advances Against Aspergillosis conference, which was held in Lisbon, Portugal. The meeting set the stage for the world’s leading aspergillosis academics, researchers and clinicians to discuss all aspects of Aspergillus infection and research.
Speakers were selected on the basis of research that actively advances the field, and the presenting delegates represented a truly international group, with new talent and perspectives on aspergillosis. In addition, leading clinicians and scientists studying Zygomycetes and mucormycosis presented their work for the first time in this forum.
A broad range of sessions played host to talks that were, in many cases, directly applicable to clinical practice as well as to further research. Topics included optimizing antifungal therapy, the immune response, future therapies, Aspergillus in the host, airways and disease, diagnostic lab challenges, patient management, resistance, mechanisms, mucormycosis, and aspergillosis risk.
Further to the research and poster presentations, the conference included the National Aspergillosis Centre patients’ meeting, which was streamed online, and the launch of the first World Aspergillosis Day (1st February). There was also a unique opportunity for delegates to discuss clinical development topics for invasive, chronic and allergic aspergillosis with representatives from the FDA and PMDA.